Unicycive Therapeutics: Funding, Investors & Team (Sep 2026)
Unicycive Therapeutics specializes in developing treatment programs for kidney diseases that have not yet been adequately addressed. Its goal is to create new therapies that target chronic kidney disease, Gitelman's Syndrome, and acute kidney disease by modifying electrolyte and ion levels and addressing underlying mitochondrial issues and inflammation. Founded in 2016, Unicycive Therapeutics is based in Los Altos, California.
Unicycive Therapeutics has raised $50.0M across 1 funding round on record, the most recent an undisclosed round of $50.0M announced in Mar 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Unicycive Therapeutics Company Profile and Key Stats
Latest funding round on record: Mar 2024.
Unicycive Therapeutics Funding Rounds
Unicycive Therapeutics Founders and Leadership Team
Contact details for the Unicycive Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Unicycive Therapeutics Funding Compared to Other Biotechnology Startups
Unicycive Therapeutics' latest round of $50.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Unicycive Therapeutics in Biotechnology and Los Altos
Companies Similar to Unicycive Therapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Unicycive Therapeutics Funding FAQs
What does Unicycive Therapeutics do?
Unicycive Therapeutics specializes in developing treatment programs for kidney diseases that have not yet been adequately addressed. Its goal is to create new therapies that target chronic kidney disease, Gitelman's Syndrome, and acute kidney disease by modifying electrolyte and ion levels and addressing underlying mitochondrial issues and inflammation. Founded in 2016, Unicycive Therapeutics is based in Los Altos, California.
How much funding has Unicycive Therapeutics raised?
Unicycive Therapeutics has raised $50.0M across 1 round on record. The most recent is an undisclosed round of $50.0M announced in Mar 2024.
When did Unicycive Therapeutics last raise funding?
Unicycive Therapeutics' most recent funding round on record is an undisclosed round of $50.0M, announced in Mar 2024.
Who founded Unicycive Therapeutics?
FundedIQ lists Shalabh Gupta (Founder) at Unicycive Therapeutics.
Where is Unicycive Therapeutics headquartered?
Unicycive Therapeutics is based in Los Altos, California, United States.
How many employees does Unicycive Therapeutics have?
Unicycive Therapeutics is in the 11-50 employee band.
How does Unicycive Therapeutics' funding compare to other Biotechnology startups?
Unicycive Therapeutics' latest round of $50.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Unicycive Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Unicycive Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.